FDA accepts biologics license application and grants priority review for tafasitamab and lenalidomide for treatment of relapsed/refractory diffuse large B cell lymphoma

Submission for tafasitamab, an investigational monoclonal antibody directed against CD19, is based on primary analysis data from the L-MIND trial of tafasitamab in combination with lenalidomide and the retrospective observational matched control cohort Re-MIND.


Biospace Inc.